D-0739-2021 Class II Terminated
FDA drug recall D-0739-2021 was initiated by Teva Pharmaceuticals USA on Jul 29, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 34,100 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 25, 2021
- Initiation Date
- Jul 29, 2021
- Termination Date
- Jun 4, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 34,100 vials
Product description
Norepinephrine Bitartrate Injection, USP 4 mg/4 mL, 4 mL single dose vials, packaged in 10 vial cartons (NDC 0703-1153-03) Rx only, Teva Pharmaceuticals USA Inc. North Wales, PA 19454, vial NDC 0703-1153-01
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
Product was distributed Nationwide, including Puerto Rico.
Code information
Lot #: 31329045B, exp. date 07/2021; 31329077B, exp. date 08/2021; 31329312B, exp. date 09/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0739-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026